Positive therapy outcome of lung squamous cell cancer: A case report

Liu,Ying; Yang,Jian; Sun,Xue-Jia; Lu,Sheng-Nan; Liu,Shi

doi:10.3892/etm.2022.11360

June-2022 Volume 23 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2022 Volume 23 Issue 6

Full Size Image

Case Report

Positive therapy outcome of lung squamous cell cancer: A case report

Authors:
- Ying Liu
- Jian Yang
- Xue-Jia Sun
- Sheng-Nan Lu
- Shi Liu
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154000, P.R. China, Department of Radiology Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Department of Ultrasonic Imaging, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China, Central Laboratory, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang 161000, P.R. China
Article Number: 433
|
Published online on: May 9, 2022

https://doi.org/10.3892/etm.2022.11360
Expand metrics +

Abstract

Abstract. Lung cancer is a rapidly progressing disease with a poor prognosis. Lung squamous cell cancer (LSCC) accounts for 20‑30% of lung cancer cases. Conventional chemotherapy and radiotherapy are the common options for LSCC. Nevertheless, the outcomes of these treatments are still unsatisfactory. The present report describes a rare case of LSCC with pericardial, cervical lymph node and extensive mediastinal lymph node metastases, who still survives today, in March 2022, more than 10 years after therapy and, therefore, this case study indicates a possible treatment regimen for patients with a similar condition. In conclusion, gemcitabine and cisplatin followed by radiotherapy were an effective treatment against pericardial and lymph node metastases from LSCC.

View Figures

View References

1	Tan PS, Bilger M, de Lima Lopes G, Acharyya S and Haaland B: Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations. Cancer Med. 6:1847–1860. 2017.PubMed/NCBI View Article : Google Scholar
2	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018.PubMed/NCBI View Article : Google Scholar
3	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
4	Alexander M, Kim SY and Cheng HY: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020.PubMed/NCBI View Article : Google Scholar
5	Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 26:3552–3559. 2008.PubMed/NCBI View Article : Google Scholar
6	Lemjabbar-Alaoui H, Hassan OU, Yang YW and Buchanan P: Lung cancer: Biology and treatment options. Biochim Biophys Acta. 1856:189–210. 2015.PubMed/NCBI View Article : Google Scholar
7	Liu TT, He Z, Dang J and Li G: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: A systematic review and network meta-analysis. Radiat Oncol. 14(55)2019.PubMed/NCBI View Article : Google Scholar
8	Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, et al: NCCN guidelines insights: Non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 16:807–821. 2018.PubMed/NCBI View Article : Google Scholar
9	Ma D, Wang J, Hao X, Wang Y, Hu X, Xing P and Li J: Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. Thorac Cancer. 8:482–488. 2017.PubMed/NCBI View Article : Google Scholar
10	Yang CH, Tsai CM, Wang LS, Lee YC, Chang CJ, Lui LT, Yen SH, Hsu C, Cheng AL, Liu MY, et al: Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer. 86:190–195. 2002.PubMed/NCBI View Article : Google Scholar
11	Zwitter M, Kovac V, Smrdel U and Strojan P: Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 1:662–666. 2006.PubMed/NCBI
12	Das M, Donington JS, Murphy J, Kozak M, Eclov N, Whyte RI, Hoang CD, Zhou L, Le QT, Loo BW and Wakelee H: Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Clin Lung Cancer. 12:280–285. 2011.PubMed/NCBI View Article : Google Scholar
13	Driesen P, Lambrechts M, Kraaij K, Soldatenkova V, Chouaki N and Colinet B: A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Ther Adv Med Oncol. 5:159–168. 2013.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Positive therapy outcome of lung squamous cell cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles